Is NuScale's Decline the Definitive Contrarian Move in AI?
Current Market Sentiment: NuScale Power's shares are trading at a 52-week low due to disappointing earnings and legal challenges, leading to significant market distress and uncertainty among investors.
Long-Term Opportunities: Despite short-term operational hurdles, NuScale is positioned to capitalize on the growing demand for clean, reliable power, particularly in the context of the AI revolution, which is expected to drive energy needs significantly.
Financial Stability: NuScale maintains a solid balance sheet with a favorable ratio of liquid assets to liabilities, providing a multi-year operational runway that supports its growth and strategic goals without needing to raise capital under unfavorable conditions.
Regulatory Advantages: The company has received exclusive regulatory design certification from the U.S. Nuclear Regulatory Commission, positioning it as a leading provider for small modular reactors in the U.S. market, which could enhance its competitive edge in the energy sector.
Trade with 70% Backtested Accuracy
Analyst Views on SMR
About SMR
About the author

- Stock Surge: NuScale Power's shares soared 44.4% at their peak this week, indicating a significant shift in market sentiment towards the nuclear energy sector, reflecting increasing investor interest in small modular reactors (SMRs).
- Policy Support: On April 14, the White House unveiled the National Initiative for American Space Nuclear Power, aiming to deploy nuclear reactors in orbit by 2028, demonstrating strong governmental backing for nuclear energy development and enhancing NuScale Power's market outlook.
- Major Investment: On the same day, the U.K. government announced approximately £599 million (around $800 million) in funding for Rolls-Royce's SMR program, signaling a rising global demand for SMRs, thereby reinforcing NuScale Power's commercial viability.
- Market Outlook: Although NuScale Power's fundamentals remain unchanged and it faces issues with its exclusive commercialization partner ENTRA1 Energy, the improving perception of nuclear energy may attract more investor interest in the company.
- Class Action Notice: Rosen Law Firm reminds investors who purchased NuScale Power Class A common stock between May 13, 2025, and November 6, 2025, to apply as lead plaintiffs by April 20, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Participants can obtain compensation without any upfront costs through a contingency fee arrangement, which reduces the financial burden on investors and encourages more affected shareholders to join the lawsuit.
- Lawsuit Background: The lawsuit alleges that NuScale failed to disclose ENTRA1 Energy LLC's lack of experience in the nuclear sector during the class period, exposing investors to significant risks that could impact the company's future commercialization strategy.
- Law Firm Advantages: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its extensive experience and success in handling such cases, prompting investors to carefully select qualified legal counsel.
- Stock Price Decline: Since the beginning of 2026, NuScale Power's shares have lost nearly 30% of their value, despite a 15% single-day gain on April 15, indicating market concerns about its future prospects that could undermine investor confidence.
- Significant Losses: The company reported a net loss exceeding $660 million last year, marking its fourth consecutive year of losses, which highlights the financial strain in developing small modular reactors (SMRs) and may limit its ability to raise capital.
- Bleak Profitability Outlook: Analysts do not expect NuScale Power to achieve profitability in the next two fiscal years, with potential profitability not anticipated until this decade, increasing reliance on external capital during market downturns and heightening financial risks.
- Capital Raising Challenges: With its market cap plummeting from $8 billion to $4 billion, NuScale Power faces a tougher fundraising environment, likely resulting in higher borrowing costs and shareholder dilution risks, further impacting its operational and growth plans.
- Poor Market Performance: Since the beginning of 2026, NuScale Power's stock has lost nearly 30% of its value, despite a 15% single-day gain on April 15, indicating a troubling trend that may undermine investor confidence regarding its future profitability.
- Escalating Financial Losses: The company reported a net loss exceeding $660 million last year, marking its fourth consecutive year of losses, and analysts predict it will remain unprofitable for at least the next two fiscal years, increasing reliance on external capital to sustain operations.
- Capital Raising Challenges: Following a market sell-off, NuScale Power's market cap has plummeted to $4 billion from $8 billion just months ago, complicating its ability to secure loans under favorable terms, while the risk of shareholder dilution looms larger at lower stock prices.
- Slow Technological Progress: Although the small modular reactor (SMR) market holds significant potential, estimated at $10 trillion, NuScale Power's first facility may not be operational until 2030 at the earliest, with the technology yet to achieve meaningful scale, placing the company at a competitive disadvantage.

Stakeholder Update: Fluor Corporation reports a decrease in its stake in NuScale Power Corporation to 3.9% as of April 15.
Previous Stake Comparison: This is a reduction from a prior stake of 7.8% reported on April 9.
- PayPal Lawsuit Overview: From February 2024 to February 2026, PayPal is accused of overstating its ability to execute business initiatives, misleading investors about its prospects, with a lead plaintiff motion deadline set for April 20, 2026.
- NuScale Power Risk Disclosure: During the period from May to November 2025, NuScale Power allegedly failed to disclose significant risks associated with its nuclear projects, prompting investors to act by April 20, 2026, indicating a loss of confidence in the company's future.
- Corcept Therapeutics Regulatory Issues: Between October 2024 and December 2025, Corcept is accused of not disclosing FDA concerns regarding the effectiveness assessment of its drug, misleading investors about its business outlook, with a lead plaintiff motion deadline of April 21, 2026.
- Navan, Inc. IPO Controversy: Navan is accused of failing to disclose a 39% increase in sales and marketing expenses during its 2025 IPO, negatively impacting its revenue and market performance, with a lead plaintiff motion deadline of April 24, 2026.









